Select Language
GPRC5D
GPRC5D Overview
| English Name | G-protein coupled receptor family C group 5member D | Approved Drugs | 1 |
| Drugs in Clinical Trials | 40 | Target Synonym | G Protein-Coupled Receptor Class C Group 5 Member D，G-Protein Coupled Receptor Family C Group 5 Member D，G Protein-Coupled Receptor， Class C， Group 5， Member D，G Protein-Coupled Receptor， Family C， Group 5， Member D，GPRC5D，Orphan G-Protein Coupled Receptor |
| Highest Development Stage | Approved | ||
| English Name | G-protein coupled receptor family C group 5member D |
| Target Synonym | G Protein-Coupled Receptor Class C Group 5 Member D，G-Protein Coupled Receptor Family C Group 5 Member D，G Protein-Coupled Receptor， Class C， Group 5， Member D，G Protein-Coupled Receptor， Family C， Group 5， Member D，GPRC5D，Orphan G-Protein Coupled Receptor |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 40 |
| Highest Development Stage | Approved |
GPRC5D Product List
- Product Category
Protein (11)Cell (2)
- Product Status
Launched (13)
- Species
Cynomolgus (2)Human (9)Mouse (2)
- Tag
His Tag & Flag Tag (4)- (8)GFP Tag (1)
- Conjugate
Unconjugated (7)- (2)GFP Fusion (1)Biotin-labeled (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT GPD-H52D6 |  Human | HEK293 | Human GPRC5D Full Length Protein, Flag,His Tag (Nanodisc) |  |  |  |  Add to Cart |
HOT GPD-H52P7 | Human | HEK293 | Human GPRC5D Full Length Protein (VLP) | | Add to Cart | ||
CCHO-STP078 | Human | CHO | CHO/Human GPRC5D Stable Cell Line |  | Add to Cart | ||
CHEK-STP042 | Human | HEK293 | HEK293/Human GPRC5D Stable Cell Line | | Add to Cart | ||
GPD-H52D5 | Human | HEK293 | Human GPRC5D Full Length Protein, Flag,His Tag (Detergent) |  | | Add to Cart | |
GPD-H82D5 | Human | HEK293 | Biotinylated Human GPRC5D Full Length Protein, Flag,His,Avitag™ (Detergent) |  | | Add to Cart | |
GPD-H82D7 | Human | HEK293 | Biotinylated Human GPRC5D Full Length Protein, Flag,His,Avitag™ (Nanodisc) |  | | Add to Cart | |
GPD-H82P3 | Human | HEK293 | Biotinylated Human GPRC5D Full Length Protein (VLP) | | Add to Cart | ||
GPD-HF2P7 | Human | HEK293 | Fluorescent Human GPRC5D Full Length Protein (VLP) | | Add to Cart | ||
GPD-M52D3 |  Mouse | HEK293 | Mouse GPRC5D Protein, Flag,His Tag (Detergent) |  | | Add to Cart |
Total: 13
- 1
- 2
GPRC5D Background
G-protein coupled receptor family C group 5 member D (GPRC5D) is a retinoic acid-inducible 40 kDa protein with seven transmembrane segments and a short N terminal extracellular region. Widely expressed in the peripheral system. Expression pattern is high in pancreas, medium in kidney, small intestine, spleen and testis, low in lung, colon, leukocyte, prostate and thymus and not detectable in brain, heart, liver, placenta, skeletal muscle and ovary.
GPRC5D Synonyms
GPRC5D,G-protein coupled receptor family C group 5 member D
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| GPRC5D VHH - 01 | PCC | Monoclonal | Nanobody | Hematological Malignancy | Multiple myeloma |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) | Phase 3 Clinical | Peking University People'S Hospital | Acquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome | Details | |
| QLS-32015 | QLS-32015; QLS32015 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Ramantamig | JNJ-79635322; JNJ-5322 | Phase 3 Clinical | Janssen Research & Development Llc | Multiple Myeloma | Details |
| Arlocabtagene autoleucel | BMS986393; BMS-986393; CC-95266 | Phase 3 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| LM-305 | LM-305 | Phase 2 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
| REGN-17372 | REGN17372; REGN-17372 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| GPRC5D/CD3 BiTEs | GPRC5D/CD3 BiTEs | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details |
| BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Multiple Myeloma | Details | |
| BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health | Multiple Myeloma; Plasmacytoma | Details | |
| AZD-0305 | AZD0305; AZD-0305 | Phase 2 Clinical | Astrazeneca Plc | Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Multiple Myeloma | Details | |
| BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| CT-071 | CT071; CT-071 | Phase 2 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy（Institute of Hematology & Blood Diseases Hospital） | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details | |
| Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| Ori-CAR-017 | Ori-CAR-017; GPRC5D-CAR-T | Phase 2 Clinical | OriCell Therapeutics Co Ltd | Blood Protein Disorders; Cardiovascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases | Details |
| LBL-034 | LBL-034 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Multiple Myeloma; Neoplasms | Details |
| anti-GPRC5D CAR T-cell Therapy (Dana-Farber Cancer Institute/Memorial Sloan Kettering Cancer Center/Roswell Park Comprehensive Cancer Center) | Phase 1 Clinical | Dana-Farber Cancer Institute | Multiple Myeloma | Details | |
| anti-GPRC5D CAR T-cell therapy (Bristol Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details | |
| O&D-001 | O&D-001 | Phase 1 Clinical | O&D BioTech Group Co Ltd | Multiple Myeloma | Details |
| SL-0439 | SL0439; SL-0439 | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details |
| TQB-2029 | TQB2029; TQB-2029 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Multiple Myeloma | Details |
| SAR-446523 | SAR-446523 | Phase 1 Clinical | Sanofi-Aventis Gmbh | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| CM-380 | CM380; CM-380 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| OL-101 | OL-101 | Phase 1 Clinical | Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
| QLS-4131 | QLS-4131; QLS4131 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| RD-140 | RD140 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Anti-GPRC5D-CD19-CAR-T cell therapy(The Second People Hospital Of Guangdong Province) | Phase 1 Clinical | The Second People Hospital Of Guangdong Province | Multiple Myeloma | Details | |
| BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Anti-GPRC5D CAR-T Cells Therapy (Guangzhou Bio-Gene Technology Co Ltd) | Phase 1 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | OriCell Therapeutics Co Ltd, Zhejiang University | Multiple Myeloma | Details |
| CAR-GPRC5D | CAR-GPRC5D; RD-118; RD118 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Forimtamig | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| MCARH-109 | Phase 1 Clinical | Eureka Therapeutics Inc, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) | ACT-001(Acellytron Therapeutics) | Clinical | Acellytron Therapeutics | Multiple Myeloma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Talquetamab | JNJ-7564; JNJ-64407564 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TALVEY, 拓立珂 | United States | Multiple Myeloma | Janssen Biotech Inc | 2023-08-09 | Hematologic Neoplasms; Multiple Myeloma | Details |
Product Reviews
E***n2025-07-31
0People LikeGreat product and fantastic service. Product worked well following delivery and solved some of the issues we've been experiencing with assays. Service was also highly commendable, with us receiving our order just days after placing it. Technical recommendations were also very useful in deciding which variant of the protein would be best suited for our assays.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to: